Clinical Trial Update: A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial) [Phase 1, Phase 2]

View source ↗

Summary

This terminated Phase 1/2 trial (Super-dose Anti-VEGF SAVE Trial) evaluated intravitreal 2.0 mg ranibizumab for chronic OCT fluid after prior ranibizumab treatm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Subfoveal Neovascular Age-related Macular Degeneration
• Wet Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: David M. Brown, M.D. | Conditions: Age Related Macular Degeneration, Choroidal Neovascular Membrane | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2017-01-02